Ocugen, Inc.
$464.63M- Market cap
- $454.41M
- Debt
- +$28.79M
- Cash
- −$18.57M
Capital structure 94% equity / 6% debt · EV / Revenue 105.29x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $454.41M · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 ·
Decision snapshot: OCGN stock price at premium vs VNDA $1.34 current versus $0.02 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VNDA's multiple
Implied fair value · at OCGN's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OCGN FY 2025 (ended Dec 31, 2025) · VNDA FY 2025 (ended Dec 31, 2025).
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 105.29x
Capital structure 81% equity / 19% debt · EV / Revenue 1.49x
OCGN carries the larger enterprise value at $464.63M against $322.90M; VNDA trades on the lower EV / Revenue multiple (1.49x vs 105.29x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
OCUGEN, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
VANDA PHARMACEUTICALS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-2.37x
0.24x
Net debt / EBITDA
Leverage against operating earnings
-0.16x
0.05x
Cash and equivalents
Liquid reserves on the balance sheet
$18.57M
$84.85M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
IOVANCE BIOTHERAPEUTICS, INC.
OCGN vs IOVA
bluebird bio, Inc.
OCGN vs BLUE
BioNTech SE
OCGN vs BNTX
Moderna, Inc.
OCGN vs MRNA
Legend Biotech Corp
OCGN vs LEGN
Arcturus Therapeutics Holdings Inc.
OCGN vs ARCT
SUPERNUS PHARMACEUTICALS, INC.
OCGN vs SUPN
CATALYST PHARMACEUTICALS, INC.
OCGN vs CPRX
Harmony Biosciences Holdings, Inc.
OCGN vs HRMY
ELI LILLY & Co
OCGN vs LLY
INCYTE CORP
OCGN vs INCY
Sarepta Therapeutics, Inc.
OCGN vs SRPT
$28.79M
$78.23M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.